Effect of application route of the ghrelin analog BIM-28131 (RM-131) on body weight and body composition in a rat heart failure model

International Journal of Cardiology

Volumn 168, Issue 3, 2013, Pages 2369-2374

  Palus, Sandra ^a,b   Von Haehling, Stephan ^a,b   Doehner, Wolfram ^a,b   Datta, Rakesh ^c   Zhang, Jundong ^c   Dong, Jesse Z ^c   Culler, Michael D ^c   Anker, Stefan D ^d   Springer, Jochen ^a,b,e  

^a DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c IPSEN   (France)

^d IRCCS SAN RAFFAELE PISANA   (Italy)

^e UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Body composition; Chronic heart failure; Ghrelin; Myocardial infarction; Weight gain

Indexed keywords

BIM 28131; GHRELIN; GROWTH HORMONE; PLACEBO; RM 131; SOMATOMEDIN C; UNCLASSIFIED DRUG; BIM-28131; OLIGOPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY COMPOSITION; BODY WEIGHT; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; FAT MASS; GROWTH HORMONE BLOOD LEVEL; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART OUTPUT; LEAN BODY WEIGHT; MALE; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; RAT; WEIGHT GAIN; ANALOGS AND DERIVATIVES; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; HEART FAILURE; INFUSION PUMP; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; BODY COMPOSITION; BODY WEIGHT; DISEASE MODELS, ANIMAL; GHRELIN; HEART FAILURE; INFUSION PUMPS; INJECTIONS, SUBCUTANEOUS; MALE; MYOCARDIAL INFARCTION; OLIGOPEPTIDES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84885596263     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.01.263     Document Type: Article

References (22)

1. S.D. Anker, P. Ponikowski, and S. Varney Wasting as independent risk factor for mortality in chronic heart failure Lancet 349 1997 1050 1053
2. S. von Haehling, and S.D. Anker Cachexia as a major underestimated and unmet medical need: facts and numbers J Cachexia Sarcopenia Muscle 1 2010 1 5
3. J. Springer, G. Filippatos, Y.J. Akashi, and S.D. Anker Prognosis and therapy approaches of cardiac cachexia Curr Opin Cardiol 21 2006 229 233
4. M. Cicoira, P.R. Kalra, and S.D. Anker Growth hormone resistance in chronic heart failure and its therapeutic implications J Card Fail 9 2003 219 226
5. J.T. Wu, and J.G. Kral Ghrelin: integrative neuroendocrine peptide in health and disease Ann Surg 239 2004 464 474
6. C. Ledderose, S. Kreth, and A. Beiras-Fernandez Ghrelin, a novel peptide hormone in the regulation of energy balance and cardiovascular function Recent Pat Endocr Metab Immune Drug Discov 5 2011 1 6
7. M. Nakazato, N. Murakami, and Y. Date A role for ghrelin in the central regulation of feeding Nature 409 2001 194 198
8. N. Nagaya, M. Uematsu, and M. Kojima Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure Circulation 104 2001 1430 1435
9. N. Nagaya, J. Moriya, and Y. Yasumura Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure Circulation 110 2004 3674 3679
10. Y.J. Akashi, S. Palus, and R. Datta No effects of human ghrelin on cardiac function despite profound effects on body composition in a rat model of heart failure Int J Cardiol 137 2009 267 275
11. S. Palus, R. Schur, and Y.J. Akashi Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFbx in a rat heart failure model PLoS One 6 2011 e26865
12. K. Schmidt, S. von Haehling, and W. Doehner IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia J Cachexia Sarcopenia Muscle 2 2011 105 109
13. W.J. Evans, J.E. Morley, and J. Argiles Cachexia: a new definition Clin Nutr 27 2008 793 799
14. T. Kato, S. Niizuma, and Y. Inuzuka Analysis of liver metabolism in a rat model of heart failure Int J Cardiol 161 3 Nov 29 2012 130 136
15. T. Akamizu, and K. Kangawa Ghrelin for cachexia J Cachexia Sarcopenia Muscle 1 2010 169 176
16. M. Volterrani, P. Desenzani, and R. Lorusso Haemodynamic effects of intravenous growth hormone in congestive heart failure Lancet 349 1997 1067 1068
17. K. Kalantar-Zadeh, T.B. Horwich, and A. Oreopoulos Risk factor paradox in wasting diseases Curr Opin Clin Nutr Metab Care 10 2007 433 442
18. S.K. Das, S. Eder, and S. Schauer Adipose triglyceride lipase contributes to cancer-associated cachexia Science 333 2011 233 238
19. K.C. Fearon Cancer cachexia and fat-muscle physiology N Engl J Med 365 2011 565 567
20. K.J. Whittlesey, and L.D. Shea Delivery systems for small molecule drugs, proteins, and DNA: the neuroscience/biomaterial interface Exp Neurol 190 2004 1 16
21. L. Brown, C. Munoz, L. Siemer, E. Edelman, and R. Langer Controlled release of insulin from polymer matrices. Control of diabetes in rats Diabetes 35 1986 692 697
22. J. Bloch, E.G. Fine, N. Bouche, A.D. Zurn, and P. Aebischer Nerve growth factor- and neurotrophin-3-releasing guidance channels promote regeneration of the transected rat dorsal root Exp Neurol 172 2001 425 432